Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...
Starboard's Jeff Smith told Pfizer in a meeting last week that they need to improve their return on investments in R&D and ...
Hedge fund Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's ...
Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets ...
Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential ...
The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.
Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...
Activist investor Starboard Value reportedly has taken a large stake in consumer health products maker Kenvue.
Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month, now reportedly has ...
Starboard has a $1 billion stake in Pfizer and an unknown but "sizable" stake in Kenvue, according to earlier media reports.